Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $42,627.62 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 58,394 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $0.73, for a total value of $42,627.62. Following the completion of the transaction, the director owned 1,727,293 shares of the company’s stock, valued at $1,260,923.89. This represents a 3.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $34,533.36.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $69,650.76.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total value of $45,849.00.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $0.65 on Thursday. The business’s fifty day moving average price is $0.81 and its 200-day moving average price is $0.86. The stock has a market capitalization of $31.60 million, a price-to-earnings ratio of -0.48 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 1-year low of $0.53 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.14. Equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after buying an additional 221,766 shares in the last quarter. Susquehanna International Group LLP increased its stake in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Werewolf Therapeutics in the 3rd quarter worth $304,000. Vanguard Group Inc. increased its stake in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after buying an additional 109,796 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HOWL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, April 7th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.